Emerging Clinical Trials: Novel Approaches in Second-Line ES-SCLC
Panelists discuss how first-line chemoimmunotherapy has become the standard for extensive-stage small cell lung cancer (ES-SCLC) based on trials such as IMpower133 and CASPIAN, while emerging agents such as DLL3-targeted therapies show promise in the relapsed setting, highlighting the need for personalized approaches and continued clinical trial participation.
EP: 1.ES-SCLC vs. LS-SCLC: Critical Differences in Disease Burden and Patient Prognosis
EP: 2.Current Treatment Paradigm: Evolution of First-Line Therapy for ES-SCLC
EP: 3.Addressing Critical Unmet Needs in ES-SCLC Patient Management
EP: 4.Emerging Clinical Trials: Novel Approaches in Second-Line ES-SCLC
Summary for Physicians:
First-Line Trials:
• IMpower133
o Atezolizumab plus carboplatin/etoposide
o Improved overall survival (OS): 12.3 vs 10.3 months
o Progression-free survival (PFS) benefit; manageable safety profile
• CASPIAN
o Durvalumab plus platinum/etoposide
o OS benefit: 13.0 vs 10.3 months
o Triplet (with tremelimumab): no added benefit, more toxicity
Second Line and Beyond:
• DeLLphi-301
o Tarlatamab (DLL3-targeting bispecific)
o Promising response rates in relapsed small cell lung cancer
o Cytokine release syndrome observed; mostly low grade
• IMforte
o Atezolizumab maintenance post first line
o No significant OS/PFS improvement
o Safety consistent with prior data
• DAREON-8
o Dareonimab in later-line setting
o Early data: modest activity, favorable safety
o Awaiting mature efficacy results
Impact on Treatment Strategies:
• Chemotherapy plus PD-L1 inhibitors: standard first-line
• Limited options post progression
• Novel agents (eg, DLL3 targeted) offer new hope
• Emphasis on personalized treatment and clinical trials
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma
June 20th 2022A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.
